Inizia
ReutersReuters

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

RefinitivMeno di 1 minuto di lettura
BCAB

Bioatla Inc BCAB:

  • BIOATLA PRESENTS PROMISING INTERIM DATA FROM ITS PHASE 1 TRIAL WITH BA3182 IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT ESMO 2025

Azioni USAReuters
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Accedi o crea un account gratuito per leggere queste notizie

Altre notizie da Reuters